Detection of Multiple HPV Types in Liquid Biopsies of Cervical Neoplasia
Clinical Chemistry · 2024
DOI: 10.1093/clinchem/hvad182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, 2024. Verfasst von Johanna Herbst und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Background
More than 95% of cervical cancers and their precancerous lesions are caused by human papillomavirus (HPV). Cell-free (cf) HPV DNA detection in blood samples may serve as a monitoring tool for cervical cancer.
Methods
In our methodological study, an HPV panel for simultaneous detection of 24 types using mass spectrometry-based analysis was developed for liquid biopsy approaches and tested on HPV positive cell lines, plasmid controls, and cervical high-grade squamous intraepithelial lesions (HSIL) in positive smear samples (n = 52). It was validated in cfDNA blood samples (n = 40) of cervical cancer patients.
Results
The HPV panel showed proficient results in cell lines and viral plasmids with a limit of detection of 1 IU (international units)/µL for HPV16/18 and 10GE/µL for HPV11/31/33/39/45/51/52/58/59 and a specificity of 100% for the tested HPV types. In cervical smear samples, HPV DNA was detected with a sensitivity of 98.14%. The overall agreement between the new HPV panel and clinical records was 97.2% (κ = 0.84). In cervical cancer cfDNA, 26/40 (65.0%) tested positive for any HPV type, with most infections due to hrHPV (24/26). HPV positive samples were found in all FIGO stages, with the highest positivity ratio in FIGO III and IV. Even the lowest stage, FIGO I, had 12/23 (52.2%) patients with a positive HPV plasma status.
Conclusions
This proof-of-concept paper shows that the described assay produces reliable results for detecting HPV types in a multiplex mass spectrometry-based assay in cervical smear and cfDNA with high specificity and sensitivity in both cohorts. The assay shows potential for liquid biopsy-based applications in monitoring cervical cancer progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Agena Bioscience GmbH, Hamburg, Germany.
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Radiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
ORCID-Profile: Johanna Herbst, Katharina Prieske, Harriet Wikman
Zitieren
APA
Herbst, J., Vohl, V., Krajina, M., Leffers, M., Kropidlowski, J., Prieske, K., Jaeger, A., Oliveira Ferrer, L., Schmalfeldt, B., Goy, Y., Burandt, E., Pantel, K., Vollmert, C., Sartori, A., Woelber, L., Effenberger, K., & Wikman, H. (2024). Detection of Multiple HPV Types in Liquid Biopsies of Cervical Neoplasia. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvad182
Vancouver
Herbst J, Vohl V, Krajina M, Leffers M, Kropidlowski J, Prieske K, et al. Detection of Multiple HPV Types in Liquid Biopsies of Cervical Neoplasia. Clinical Chemistry. 2024. doi:10.1093/clinchem/hvad182
BibTeX
@article{Herbst2024,
author = {Herbst, Johanna and Vohl, Vanessa and Krajina, Maroje and Leffers, Markus and Kropidlowski, Jolanthe and Prieske, Katharina and Jaeger, Anna and Oliveira Ferrer, Leticia and Schmalfeldt, Barbara and Goy, Yvonne and Burandt, Eike and Pantel, Klaus and Vollmert, Caren and Sartori, Alexander and Woelber, Linn and Effenberger, Katharina and Wikman, Harriet},
title = {Detection of Multiple HPV Types in Liquid Biopsies of Cervical Neoplasia},
journal = {Clinical Chemistry},
year = {2024},
doi = {10.1093/clinchem/hvad182}
}
EUVIMED